Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Pertzye
Generic Name
Pancrelipase
Active Ingredient
Pancrelipase AmylaseCategory
Vitamin C [EPC]
Variants
4
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Pertzye, you must consult a qualified healthcare professional.
| 15125 [USP'U]/1 | CAPSULE, DELAYED RELEASE | ORAL | 59767-004 |
Detailed information about Pertzye
Pancrelipase Amylase is a critical digestive enzyme component used in pancreatic enzyme replacement therapy (PERT) to manage exocrine pancreatic insufficiency and facilitate the breakdown of complex carbohydrates.
Dosage for Pancrelipase Amylase is highly individualized and is typically calculated based on the lipase component of the pancrelipase mixture, as fat malabsorption is usually the most clinically significant issue. However, the amylase component is always present in a standardized ratio.
For adults with chronic pancreatitis or pancreatic surgery, the starting dose typically ranges from 25,000 to 50,000 USP units of lipase per meal. This corresponds to a proportional amount of amylase (often 2 to 4 times the lipase units, depending on the brand). The dose is then titrated upward based on the reduction of steatorrhea (fatty stools) and the improvement of nutritional status. Doses for snacks are usually half of the full meal dose.
In children, particularly those with Cystic Fibrosis, dosing is often weight-based or based on the amount of fat ingested.
According to the Cystic Fibrosis Foundation guidelines, doses should generally not exceed 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day to minimize the risk of fibrosing colonopathy.
Since Pancrelipase Amylase is not systemically absorbed, dose adjustments for renal impairment are generally not required. However, patients with end-stage renal disease should be monitored for hyperuricemia, as porcine enzymes contain purines that can increase uric acid levels.
No specific dose adjustments are provided for hepatic impairment, as the enzymes act locally in the gut lumen.
Clinical trials have not identified significant differences in response between elderly and younger patients. Dosing should remain focused on clinical symptom control (e.g., stool consistency, weight maintenance).
If you miss a dose, skip it and take your next dose with your next meal or snack. Do not attempt to 'double up' on doses to make up for a missed one. If you forget to take the medication until the meal is finished, your doctor may advise taking it immediately, but it is less effective once food has left the stomach.
While Pancrelipase Amylase is not absorbed, extremely high doses can cause adverse effects. Signs of overdose may include severe constipation, nausea, abdominal cramping, or transient hyperuricemia (high uric acid in the blood). In the event of a massive ingestion, contact a poison control center and seek supportive care.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance, as improper dosing can lead to malnutrition or severe GI complications.
Most side effects associated with Pancrelipase Amylase are gastrointestinal in nature, often reflecting the body's adjustment to increased enzymatic activity or the underlying pancreatic condition.
Pancrelipase Amylase is a porcine-derived product. Patients should be aware that while the manufacturing process includes steps to inactivate viruses, there remains a theoretical risk of transmitting viral diseases from pigs to humans. To date, no such transmissions have been documented in clinical practice. Patients with religious or ethical objections to porcine products should discuss alternatives with their healthcare provider.
No FDA black box warnings for Pancrelipase Amylase. However, the risk of fibrosing colonopathy is a major safety concern that is highlighted in the 'Warnings and Precautions' section of all PERT labels.
There are no absolute drug-drug contraindications where Pancrelipase Amylase must never be used; however, certain combinations significantly impair its efficacy.
Pancrelipase Amylase is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. It is also unknown whether Pancrelipase Amylase can cause fetal harm or affect reproductive capacity. However, since these enzymes are not absorbed systemically, the risk to the fetus is theoretically very low. The primary concern during pregnancy is ensuring the mother maintains adequate nutrition and weight gain, which requires effective management of EPI. Healthcare providers typically conclude that the benefits of PERT during pregnancy outweigh the potential risks.
It is not known whether Pancrelipase Amylase is excreted in human milk. However, because the enzymes are not systemically absorbed by the mother, they are unlikely to be present in breast milk in any significant amount. Even if trace amounts were present, they would be digested in the infant's GI tract. Breastfeeding is generally considered safe while taking PERT.
Pancrelipase Amylase is FDA-approved for use in pediatric patients, primarily for the treatment of Cystic Fibrosis.
Pancrelipase Amylase acts as an exogenous replacement for endogenous pancreatic amylase. Its primary molecular target is the alpha-1,4-glucosidic bond found in complex carbohydrates. By cleaving these bonds, the enzyme converts starch (amylose and amylopectin) into smaller saccharides. Specifically, it breaks down starch into maltose, maltotriose, and alpha-dextrins. These smaller molecules are then further broken down into glucose by brush-border enzymes (like maltase and sucrase) in the small intestine, allowing for absorption into the bloodstream.
The pharmacodynamic effect of Pancrelipase Amylase is the reduction of carbohydrate malabsorption. The dose-response relationship is complex and depends on the pH of the duodenum, the timing of the dose relative to food intake, and the gastric emptying rate. The onset of action is immediate upon reaching the duodenum. The duration of effect is limited to the transit time through the small intestine, typically 2 to 4 hours. Tolerance does not develop, as this is a replacement therapy for a physiological deficiency.
Common questions about Pertzye
Pancrelipase Amylase is primarily used to treat Exocrine Pancreatic Insufficiency (EPI), a condition where the pancreas does not produce enough enzymes to digest food. This occurs most commonly in patients with Cystic Fibrosis, chronic pancreatitis, or those who have had pancreatic surgery. The amylase component specifically helps the body break down starches and complex carbohydrates into simple sugars that can be absorbed. Without this enzyme, patients experience bloating, gas, and malnutrition. Your healthcare provider will determine the correct dose based on your specific digestive needs.
The most frequently reported side effects include abdominal pain, gas (flatulence), nausea, and headache. Because the medication works directly in the digestive tract, many patients feel mild cramping or changes in bowel habits as their body adjusts to the enzymes. Some people may also experience dizziness or a sore throat if the capsule is not swallowed quickly. Most of these symptoms are mild and resolve as the body becomes accustomed to the therapy. However, any severe or persistent pain should be reported to a doctor immediately.
While there is no direct chemical interaction between alcohol and Pancrelipase Amylase, drinking alcohol is strongly discouraged for patients with pancreatic issues. Alcohol is a primary toxin to the pancreas and can cause further damage, worsening the very condition the medication is trying to treat. In cases of chronic pancreatitis, alcohol consumption can lead to painful flare-ups and decrease the effectiveness of your overall treatment plan. It is best to discuss your alcohol consumption habits honestly with your healthcare provider to ensure the best outcome for your health.
Pancrelipase Amylase is generally considered safe during pregnancy because it is not absorbed into the mother's bloodstream and therefore cannot reach the developing fetus. The FDA categorizes it as Category C, meaning while there aren't extensive human studies, the clinical necessity of maintaining the mother's nutrition usually outweighs any theoretical risks. Malnutrition during pregnancy poses a much greater risk to the baby than the enzyme therapy itself. Always inform your obstetrician if you are taking pancreatic enzymes so they can monitor your nutritional status and weight gain closely.
Pancrelipase Amylase begins working as soon as it reaches the small intestine and comes into contact with food. For most patients, this happens within 30 to 60 minutes after taking the capsule with a meal. You may notice an improvement in symptoms like bloating and gas within the first few days of starting therapy. However, it may take several weeks of dose adjustments by your doctor to find the 'perfect' dose that completely normalizes your digestion and stool consistency. Consistency is key; the medication must be taken with every meal to be effective.
You should not stop taking Pancrelipase Amylase without consulting your healthcare provider. For most patients with conditions like Cystic Fibrosis or a removed pancreas, this is a lifelong medication. If you stop taking it, your body will immediately lose its ability to digest carbohydrates and fats properly. This will lead to the return of symptoms such as fatty stools, severe gas, abdominal pain, and eventual weight loss and vitamin deficiencies. If you are experiencing side effects that make you want to stop the medication, talk to your doctor about adjusting the dose instead.
If you forget to take your dose during a meal, you can take it immediately after you finish eating. However, if a significant amount of time has passed since your meal, it is usually better to simply skip the missed dose and take your regular dose with your next meal or snack. Do not take a double dose to make up for the one you missed, as this can increase the risk of side effects like constipation or stomach pain. Keeping your medication in a portable pill container can help ensure you always have it with you when you eat.
Pancrelipase Amylase can lead to weight gain, but this is usually a positive and intended effect of the medication. Patients with pancreatic insufficiency often lose weight because they cannot absorb the calories from the food they eat. By helping your body digest and absorb nutrients, the enzymes allow you to regain lost weight and maintain a healthy nutritional status. If you experience sudden or excessive weight gain that seems unrelated to improved nutrition, you should discuss this with your doctor to rule out other causes like fluid retention.
Pancrelipase Amylase can be taken with most medications, but there are a few exceptions. It can interfere with the absorption of iron supplements and may decrease the effectiveness of certain diabetes medications like acarbose. Additionally, some antacids can interfere with the enzyme's protective coating. It is very important to provide your doctor and pharmacist with a full list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking. They can help you schedule your doses to avoid any potential interactions.
Currently, Pancrelipase Amylase products are not considered 'interchangeable' in the same way many other generic drugs are. Because these are complex biological products derived from porcine tissue, the FDA requires each brand (like Creon, Zenpep, or Pancreaze) to have its own approved application. You should not switch from one brand to another without your doctor's supervision, as the amount of enzyme and the way it is released in the gut can vary between manufacturers. Always check with your pharmacist to ensure you are receiving the specific brand prescribed by your doctor.
Other drugs with the same active ingredient (Pancrelipase Amylase)
> Warning: Stop taking Pancrelipase Amylase and call your doctor immediately if you experience any of these.
Prolonged use of Pancrelipase Amylase is generally well-tolerated because it replaces a natural physiological deficiency. However, long-term monitoring is required for:
Currently, the FDA does not mandate a Black Box Warning for Pancrelipase Amylase. However, there is a prominent Warning and Precaution regarding Fibrosing Colonopathy. The FDA-approved labeling emphasizes that this risk is highest in children under 12 years of age receiving high doses and recommends that healthcare providers strictly adhere to the dosing limits established by the Cystic Fibrosis Foundation.
Report any unusual symptoms to your healthcare provider immediately. Maintaining a 'stool diary' can help your doctor determine if side effects are related to the medication or the underlying disease.
To ensure the safety and efficacy of Pancrelipase Amylase, healthcare providers typically order the following:
Pancrelipase Amylase has no known effect on the ability to drive or operate heavy machinery. It does not cause sedation or cognitive impairment.
While alcohol does not directly interact with the chemistry of Pancrelipase Amylase, patients with chronic pancreatitis are strongly advised to avoid alcohol. Alcohol consumption is a leading cause of pancreatic damage and can significantly worsen the symptoms of exocrine pancreatic insufficiency, rendering the enzyme therapy less effective.
Pancrelipase Amylase is typically a lifelong therapy for patients with permanent pancreatic damage (e.g., CF or total pancreatectomy). If the medication is stopped suddenly, symptoms of malabsorption (steatorrhea, weight loss, abdominal pain) will return quickly. There is no 'withdrawal syndrome,' but the return of the underlying disease symptoms can be severe. Tapering is usually not required unless the patient's pancreatic function has somehow improved.
> Important: Discuss all your medical conditions, including any history of intestinal blockage or gout, with your healthcare provider before starting Pancrelipase Amylase.
To manage these interactions, healthcare providers often recommend:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for diabetes or anemia.
There is no known cross-sensitivity between Pancrelipase Amylase and synthetic medications. However, patients who are sensitive to other porcine-derived products (such as certain types of heparin or porcine insulin) should be monitored closely for allergic symptoms upon initiation of therapy.
> Important: Your healthcare provider will evaluate your complete medical history, including any religious or dietary restrictions regarding porcine products, before prescribing Pancrelipase Amylase.
Clinical studies have included patients aged 65 and older. No overall differences in safety or effectiveness have been observed between geriatric and younger patients. However, elderly patients may be more susceptible to constipation, a common side effect of PERT. Dehydration, which is more common in the elderly, can exacerbate this risk.
In patients with renal impairment, the clearance of uric acid is reduced. Because Pancrelipase Amylase can increase uric acid production, these patients are at a higher risk for hyperuricemia and related kidney stones. Frequent monitoring of serum uric acid is recommended for patients with a GFR below 30 mL/min.
No specific studies have been conducted in patients with hepatic impairment. However, since the drug is not metabolized by the liver and acts locally in the gut, no dose adjustment is expected to be necessary.
> Important: Special populations, particularly infants and the elderly, require individualized medical assessment and frequent monitoring of nutritional markers.
|---|---|
| Bioavailability | 0% (Not systemically absorbed) |
| Protein Binding | N/A |
| Half-life | N/A (Acts locally) |
| Tmax | N/A (Local action begins in 30-60 mins) |
| Metabolism | Digested as dietary protein in the GI tract |
| Excretion | Fecal (as degraded protein) |
Pancrelipase Amylase is a member of the Digestive Enzymes therapeutic class. It is specifically a Pancreatic Enzyme Replacement Therapy (PERT). Related medications include other components of pancrelipase, such as Lipase (for fats) and Protease (for proteins).